Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$61959.9.

  • Ascendis Pharma A's Cash from Investing Activities rose 8878.36% to -$61959.9 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 13776.66%. This contributed to the annual value of $7.5 million for FY2024, which is 9758.88% down from last year.
  • Ascendis Pharma A's Cash from Investing Activities amounted to -$61959.9 in Q3 2025, which was up 8878.36% from -$4.9 million recorded in Q2 2025.
  • Ascendis Pharma A's Cash from Investing Activities' 5-year high stood at $226.1 million during Q1 2023, with a 5-year trough of -$128.0 million in Q4 2021.
  • Moreover, its 5-year median value for Cash from Investing Activities was $7.8 million (2024), whereas its average is $13.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 111952.27% in 2023, then tumbled by 84997.45% in 2025.
  • Ascendis Pharma A's Cash from Investing Activities (Quarter) stood at -$128.0 million in 2021, then surged by 99.36% to -$813137.1 in 2022, then soared by 1119.52% to $8.3 million in 2023, then tumbled by 104.74% to -$393243.1 in 2024, then soared by 84.24% to -$61959.9 in 2025.
  • Its Cash from Investing Activities was -$61959.9 in Q3 2025, compared to -$4.9 million in Q2 2025 and -$739474.8 in Q1 2025.